Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure

Journal of Pediatric Endocrinology and Metabolism

Volumn 9, Issue 5, 1996, Pages 533-537

  Laron, Z ^a   Wang, X L ^b,c   Klinger, B ^a   Silbergeld, A ^a   Davidovits, M ^a   Eisenstein, B ^a   Wilcken, D E L ^b  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE HENRY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE; INSULIN; LIPOPROTEIN A; SOMATOMEDIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PRESCHOOL CHILD; RISK FACTOR; SCHOOL CHILD;

EID: 0029856296     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1996.9.5.533     Document Type: Article

References (26)

1. Chesney RW. Growth retardation in childhood renal disease: a hormonal or nutritional problem? Am J Nephrol 1987; 7: 253-256.
2. Maxwell H, Nair DR, Dalton RN, Rigden SP, Rees L. Differential effects of recombinant human growth hormone on glomerular filtration rate and renal plasma flow in chronic renal failure. Pediatr Nephrol 1995; 9: 458-463.
3. Fine RN, Attie KM, Kuntz J, Brown DF, Kohaut EC. Recombinant human growth hormone in infants and young children with chronic renal insufficiency. Genentech Collaborative Study Group. Pediatr Nephrol 1995; 9: 451-457.
4. Schwartz ID, Warady BA, Buchanan CL, el al. "Low-dose" growth hormone therapy during peritoneal dialysis or following renal transplantation. Pediatr Nephrol 1995; 9: 320-324.
5. Mehls O, Tynshoff B, Haffner D, W hl E, Schaefer F. The use of recombinant human growth hormone in short children with chronic renal failure [Review]. J Pediatr Endocrinol 1994; 7: 107-113.
6. 2 in children with idiopathic short stature induces a sustained increase in growth velocity. Clin Endocrinol 1994; 41: 487-493.
7. Tynshoff B, Tynshoff C, Mehls O, et al. Growth hormone treatment in children with preterminal chronic renal failure: no adverse effect on glomerular filtration rate. Eur J Pediatr 1992; 151: 601-607.
8. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DEL. Insulin, a possible mediator of the effects of growth hormone and insulin-like growth factor on circulating lipoprotein(a). 1996 (submitted).
9. Oscarsson J, Ottosson M, Wiklund O, et al. Low dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low density lipoprotein cholesterol concentrations in middle-aged men. Clin Endocrinol 1994; 41: 109-116.
10. Olivecrona H, Johansson AG, Lindh E, Ljunghall S, Berglund L, Angelin B. Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-1. Arterioscler Thromb Vase Biol 1995; 15: 847-849.
11. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease [Review]. Atherosclerosis 1994; 108: 111-126.
12. Utermann G. The mysteries of lipoprotein(a) [Review]. Science 1989; 246: 904-910.
13. Morbidity and mortality of dialysis [Review]. NIH Consensus Statement. 1993; 11: 1-33.
14. Kronenberg F, Konig P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-120.
15. Segarra A, Chacon P, Martin M, et al. Serum lipoprotein(a) levels in patients with chronic renal failure ⋯ evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: a prospective study. Nephron 1995; 69: 9-13.
16. Cressman MD, Abood D, O'Neil J, Hoff HF. Lp(a) and premature mortality during chronic hemodialysis treatment. Chem Physic Lipids 1994; 67-68: 419-427.
17. Black IW, Wilcken DEL. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism Clin Chem 1992; 38: 353-357.
18. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989; 9(Suppl 1): 119-132.
19. Wang XL, Wilcken DEL, Dudman NPB An indirect sandwich ELISA for serum and dried blood spot Lp(a) measurements, comparison to a commercial RIA. Clin ChimActa 1992; 207: 73-86.
20. Laron Z, Klinger B, Silbergeld A, Lewin B, Erster B, Gil-Ad I. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinol 1990; 123: 378-382.
21. Cowell CT, Dietsch S. Adverse events during growth hormone therapy. J Pediatr Endocrinol Metab 1995; 8: 243-252.
22. Wilcken DEL, Wang XL, Greenwood J, Lynch J Lipoprotein(a), apolipoprotein B and Al in children and coronary events in their grandparents J Pediatrics 1993; 123: 519-526.
23. Cobbaert C, Deprost L, Mulder P, Rombaut K, Gijsels G, Kesteloot H. Pubertal serum lipoprotein(a) and its correlates in Belgian schoolchildren. Int J Epidemiol 1995; 24: 78-87.
24. Querfeld U, Lang M, Friedrich JB, Kohl B, Fiehn W, Scharer K. Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease. Pediatr Res 1993; 34: 772-776.
25. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DEL. Insulin-like growth factor 1 lowers serum lipoprotein(a) during long-term treatment of patients with Laron syndrome. Metabolism 1996; in press.
26. Haffner D, Zachanewiz O, Mehls O, Heinnich U, Ritz E. The acute effect of growth hormone on CRF is obliterated in chronic renal failure. Clin Nephrol 1989; 32: 266-269.